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Abstract | Clinical and experimental data, together with epidemiological studies, have suggested that the 
pathogenesis of multiple sclerosis (MS) might involve factors that link the immune system with metabolic 
status. Moreover, recent research has shown that leptin, the adipocyte-derived hormone that controls food 
intake and metabolism, can promote experimental autoimmune encephalomyelitis, an animal model of MS. 
In patients with MS, the association of leptin with disease activity has been dissected at the molecular level, 
providing new mechanistic explanations for the role of this hormone in MS. Here, we review the intricate 
relationship between leptin and other metabolic modulators within a framework that incorporates the latest 
advances linking the CNS, immune tolerance and metabolic status. We also consider the translational 
implications of these new findings for improved management of MS.
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Introduction
leptin is an adipocyte-derived hormone, a major role of 
which is to monitor fat stores in the body and, thereby, 
regulate energy expenditure via the neuroendocrine 
system.1 in addition, leptin has been shown to influence 
immune function.2 leptin has characteristics of an early 
acute-phase reactant—similar to C-reactive protein and 
interleukin (il)-1—and can be induced by inflamma-
tory mediators such as tumor necrosis factor (tnF), il-1 
and il-6. over the past 10 years, a substantial body of 
evidence has implicated leptin as one of the main media-
tors that link nutritional status and metabolism to the 
immune response, and leptin and hypo thalamic media-
tors (as well as other adipose tissue-derived cytokines) 
seem to have key roles in these processes.2
From an epidemiological standpoint, the rising fre-
quency of autoimmune disorders and chronic inflam-
mation in affluent countries and the western world 
has prompted an increasing interest in finding new 
links between metabolism and autoimmune disease 
susceptibility.3,4 multiple sclerosis (ms) is one of the 
most common autoimmune disorders, but its etiology 
is poorly understood.5 a link between metabolism and 
ms pathogenesis has been hypothesized, particularly in 
view of the finding that proinflammatory mediators such 
as leptin maintain microenvironmental conditions that 
promote loss of immune self-tolerance.6 in this review, 
we discuss this hypothesis, and consider the possi bility 
that metabolic or nutritional interventions might directly 
influence the pathogenesis and outcome of ms. to set the 
scene, we begin with a general introduction to the roles 
of leptin in the immune system.
Leptin and the immune system
Molecular effects of leptin on T cells
the actions of leptin are mediated through the leptin 
receptor (lePr; Box 1). leptin amplifies CD4+ t-cell 
responses, and human CD4+ t lymphocytes express 
LEPR messenger rna (mrna).2 the long form of lePr, 
lePrb, is expressed on both CD4+ and CD8+ human 
t cells, and was found to be expressed on regulatory t 
(treG) cells.7 Human monocytes, which can be activated by 
high-dose leptin, also express lePrb. in addition, human 
natural killer (nK) cells show constitutive expression of 
both the long and short lePr isoforms.2
as observed with other members of the class i cyto-
kine receptor family, the binding of leptin to lePrb 
on lymphoid cells activates JaK (Janus kinase) and 
stat (signal transducer and activator of transcrip-
tion) proteins (Figure 1).8,9 the cytoplasmic tail of all 
four membrane-bound lePrs contains a box 1 motif, 
which is strongly conserved within most members of 
this receptor family, whereas a box 2 motif is found only 
in the long isoform. these two domains are involved in 
the interaction with and activation of JaK2 tyrosine 
kinase, which phosphorylates and activates members 
of the stat family such as stat1, stat5 and stat3. 
activated JaK2 then phosphorylates tyrosine resi-
dues in the intracellular domain of lePrb, thereby 
providing binding motifs for the sH protein tyrosine 
 phosphatase-2 (sHP-2) and stat proteins (Figure 1).2,8,9 
after tyrosine phosphorylation in response to JaK acti-
vation, the stat proteins translocate to the nucleus, 
where they activate gene transcription. the stat3-
dependent target genes include FOS, JUN and suppres-
sor of cytokine signaling 3 (SOCS3). Both in vitro and 
in vivo, lePrb can also stimulate sHP-2-dependent 
erK1/2 (extracellular signal- regulated kinases 1 and 2) 
activation, tyrosine phosphorylation of insulin receptor 
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substrate 1 (irs-1), and phosphatidylinositol 3-kinase 
(Pi3K) activity (Figure 1).2,8,9
in CD4+CD25− effector t cells, leptin induces stat3 
phosphorylation, but stimulation of CD4+CD25+ 
treG cells with anti-CD3/CD28—a classic t-cell recep-
tor (tCr) polyclonal stimulation—is not associated with 
induction of phosphorylation of stat3, confirming 
their hyporesponsive (anergic) state.7 soCs3, a negative 
regulator of cytokine signaling, is activated by leptin 
neutraliza tion in CD4+CD25+ t cells, in which stimu-
lation with an anti-CD3/CD28 monoclonal antibody 
induces phosphorylation of erK1/2 and cell prolifera-
tion, suggesting reversal of their anergic state on leptin 
neutralization.7 in the same subset of t cells, levels of 
cyclin-dependent kinase inhibitor p27 (p27Kip1), a mol-
ecule that is involved in the control of the cell cycle and 
t-cell anergy, remain elevated during anti-CD3/CD28-
mediated stimulation. leptin neutralization induces 
degradation of p27Kip1, which might partially explain the 
reversal of anergy and subsequent proliferation.7
The role of leptin in immunity
leptin is an acute-phase reactant, the secretion of 
which increases during bacterial infection and systemic 
Key points
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represent an attractive target to reduce autoimmune inflammation in MS
inflammation, as well as after stimulation with lipo-
polysaccaride (lPs), tnF, il-1 and il-6. in cells of 
the monocyte–macrophage lineage, leptin promotes 
activation of phagocytosis and secretion of proinflam-
matory cyto kines and leukotriene B4. in human poly-
morphonuclear neutro phils, which express lePrb, leptin 
induces the release of oxygen radicals (superoxide and 
hydrogen peroxide) and promotes chemotaxis.2
in the mixed lymphocyte reaction—an assay in which 
CD4+ lymphocytes from one individual are cultured 
together with antigen-presenting cells from another 
individual mismatched for the human leukocyte antigen 
molecules—the addition of physiological concentrations 
of leptin induced a marked dose-dependent increase in 
CD4+ t lymphocyte proliferative responses.2 leptin exerts 
differential effects, however, on proliferative responses 
and cytokine release in human naive (CD45ra+) and 
memory (CD45ro+) CD4+ t cells, both of which express 
LEPRb mrna.2 in the presence of leptin, naive t cells 
exhibit increased proliferation and il-2 production. By 
contrast, leptin has a minimal effect on the prolifera-
tion of memory t cells, in which it promotes increased 
secretion of interferon (iFn)-γ and decreased secretion 
of il-4. these findings suggest a bias of leptin towards 
inducing proinflammatory t helper 1 (tH1) responses, 
as iFn-γ is the prototypical tH1 cytokine.2
these observations indicate that leptin could represent 
a key mediator in the link between immune responses 
and metabolism. indeed, during nutritional deprivation, 
which is associated with low leptin levels, replacement of 
this hormone restored the otherwise reduced inflamma-
tory delayed-type hypersensitivity responses both in mice 
and in healthy women participating in a double-blind 
placebo-controlled study involving acute 72 h starvation 
in the presence or absence of exogenous leptin admini-
stration.10,11 our group has produced similar findings 
with recombinant leptin treatment in low-body-weight 
women with hypothalamic amenorrhea (G. matarese 
et al., unpublished work).
Leptin and autoimmune disease
Animal models of MS
leptin-deficient (ob/ob) mice show reduced production of 
il-2, iFn-γ, il-18 and tnF, and increased production 
of il-4 and il-10, in lymphocytes following antigenic 
stimulation.2 these mice have several immune abnor-
malities, including impaired cell-mediated immunity, 
abnormal CD4+ t-cell function, and thymic atrophy 
(which mainly affects the cortex of the thymus, where the 
majority of CD4+CD8+ immature t cells reside). leptin 
replacement restores normal thymic function by increas-
ing the number of CD4+CD8+ t cells, and by reducing 
their rate of apoptosis.12
importantly, ob/ob mice are resistant to the induction 
of both actively and passively induced experimental auto-
immune encephalomyelitis (eae), the most commonly 
studied animal model of ms.13 leptin administration 
converts eae resistance into susceptibility by restoring 
t-cell proliferation in response to myelin antigens and 
by shifting the predominant tH2-type responses of the 
Box 1 | The leptin receptor
The leptin receptor (LEPR) is a member of the class I cytokine receptor family, 
which includes the receptors for interleukin 6, leukemia inhibitory factor, 
granulocyte colony-stimulating factor and gp120.2 LEPR mRNA is alternatively 
spliced, giving rise to six different receptor forms known as LEPRa, LEPRb, LEPRc, 
LEPRd, LEPRe and LEPRf. The various LEPR molecules have cytoplasmic domains 
of differing lengths: LEPRb, also known as the long receptor isoform, has 302 
cytoplasmic residues, which include activation and signal transduction motifs. The 
other membrane-bound forms (LEPRa, LEPRc, LEPRd and LEPRf) have cytoplasmic 
domains consisting of 34 amino acid residues, and the soluble form (LEPRe) 
lacks some or all of the transmembrane and cytoplasmic motifs.2 The short forms 
of the LEPR are ubiquitously expressed in several tissues, where they presumably 
mediate leptin transport and degradation. LEPRb is primarily expressed, 
at high levels, in the hypothalamus, especially in the arcuate, dorsomedial, 
ventromedial and lateral hypothalamic nuclei, which secrete neuropeptides and 
neurotransmitters involved in the regulation of appetite and body weight. LEPRb 
is also expressed in fetal liver, jejunal epithelium, pancreatic β cells, ovarian 
follicular cells, vascular endothelial cells, CD34+ hematopoietic bone marrow 
precursors, and T lymphocytes.2
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ob/ob mice towards tH1-type responses. leptin adminis-
tration in eae-susceptible wild-type mice worsens eae 
by increasing the secretion of pro inflammatory cyto kines 
and by favoring the production of myelin-specific auto-
antibodies. taken together, these data suggest that leptin 
contributes to the generation of micro environmental con-
ditions that promote the loss of tolerance mechanisms 
directed towards self-reactive t cells.13
the onset of neurological symptoms following eae 
induction is typically preceded by a reduction in food 
intake and body weight, and we have provided evidence 
that a marked surge in serum leptin levels, starting after 
immunization with myelin antigens, anticipates the 
onset of the acute phase of eae.11 the systemic elevation 
of leptin probably accounts for the inhibition of food 
intake and loss of body weight observed in mice with 
eae, and directly correlates with clinical disease score 
and eae susceptibility.
acute and chronic inflammatory conditions induced 
by the administration of il-1, tnF and lPs are associ-
ated with increased leptin levels, anorexia, and loss of 
lean body mass, indicating that leptin levels could link 
anorexia and acute inflammation.14 starvation reduces 
serum leptin and impairs delayed-type hyper sensitivity 
responses to antigens. in female sJl/J mice—a strain 
that is particularly susceptible to eae—starvation for 
48 h during priming with the encephalitogenic proteo-
lipid protein (PlP)139–151 peptide reduced disease severity, 
impaired antigen- specific t-cell proliferation and iFn-γ 
production, and led to increased il-4 secretion.11 the 
effects of starvation could be reversed by in vitro and 
in vivo admini stration of recombinant leptin, so these 
data support the hypothesis that leptin, together with 
other proinflammatory cyto kines, can directly influ-
ence demyelinating disease by favoring and sustain-
ing tH1 responses in the phases that precede disease 
onset.11 notably, the increase in serum leptin observed 
after induction of inflammation during eae was accom-
panied by in situ production of leptin by pathogenic 
t cells and macrophages in lymph nodes and in acute 
demyelinating lesions in the brain and spinal cord of the 
immunized mice.
Gene microarray analysis of tH1 lymphocytes and 
active human ms lesions has revealed elevated transcrip-
tion of genes of the neuroimmunoendocrine axis, includ-
ing the leptin gene (known as LEP or OB), the transcript 
of which was abundant in tH1 cells, which are commonly 
involved in t-cell-mediated autoimmune diseases such 
as eae.15 in addition, anti-lePr anti bodies, as well as 
anti-leptin antibodies, seem to reduce the in vitro pro-
liferative response of myelin antigen-specific t lympho-
cytes, possibly by interfering with an autocrine loop that 
con tributes to the expansion and survival of tH1 cells.7 
In vivo, treatment of eae mice with anti-leptin anti-
bodies or a soluble lePr–Fc fusion protein reduced eae 
onset and severity, and mortality.16,17
leptin and obesity in human autoimmunity
in addition to multiple neuroendocrine and metabolic 
impairments, leptin-deficient (OB/OB) individuals 
display several immune abnormalities, including an 
impaired cellular immune response, abnormal cytokine 
release (lack of iFn-γ secretion, reduced il-4 and il-10 
levels, and increased tGF-β levels), a reduction in circu-
lating CD4+ t cells (especially naive cells), and impaired 
t-cell proliferation. administration of recombinant 
leptin reverses these immune abnormalities and restores 
the CD4+:CD8+ t-cell ratio, t-cell proliferative responses, 
and cytokine production.18
Hyperleptinemia is associated with proinflammatory 
conditions and autoimmunity in humans: increased 
peripheral levels of leptin have been observed in patients 
with rheumatoid arthritis, Behcet syndrome, pelvic endo-
metriosis and type 1 diabetes.19 in patients with ms, leptin 
levels are increased in both the serum and the cerebro-
spinal fluid (CsF), correlating with iFn-γ production in 
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Figure 1 | Intracellular leptin signaling in immune cells. After leptin binding to 
LEPRb, JAK2 becomes activated by autophosphorylation or cross-phosphorylation, 
and phosphorylates tyrosine residues in the receptor’s cytoplasmic domain. Four 
of the phosphorylated residues function as docking sites for cytoplasmic adaptors 
for STAT factors, particularly STAT3. STAT3 dimerizes and translocates to the 
nucleus, where it induces expression of SOCS3 and other genes. SOCS3 
participates in a feedback loop that inhibits leptin signaling by binding to 
phosphorylated tyrosines. SHP-2 is recruited to Tyr985 and Tyr974 and activates 
ERK1/2 and p38 MAPK pathways through the adaptor protein GRB2, ultimately 
inducing FOS and JUN expression. PTP-1B is localized on the surface of the 
endoplasmic reticulum, and is involved in negative regulation of LEPRb signaling 
through dephosphorylation of JAK2 after internalization of the LEPRb complex. 
JAK2 can also induce phosphorylation of the IRS1 and 2 proteins, which are 
responsible for PI3K activation. Abbreviations: ERK1/2, extracellular-signal 
regulated kinases 1 and 2; GRB2, growth factor receptor-bound protein 2; IRS, 
insulin receptor substrate; JAK2, Janus kinase 2; LEPRb, leptin receptor, long 
form; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol-3-kinase; 
PTP-1B, tyrosine-protein phosphatase non-receptor type 1; SHP-2, SHP protein 
tyrosine phosphatase-2; SOCS3, suppressor of cytokine signaling 3; STAT, signal 
transducer and activator of transcription.
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the CsF.16 moreover, t-cell lines that are reactive against 
human myelin basic protein (hmBP) produce immuno-
reactive leptin and upregulate the expression of lePr 
after activation with hmBP. treatment in vitro with anti-
leptin or anti-lePr neutralizing antibodies inhibits pro-
liferation of these cells in response to hmBP, as well as the 
production of proinflammatory cytokines in peripheral 
blood mononuclear cells from patients with ms.16
at the molecular level, the expression of lePr is higher 
in CD8+ t cells and monocytes from patients with ms 
who are in relapse than in those who are in remission (or 
healthy controls). relapsing patients display high levels 
of phospho-stat3 (P-stat3) and low levels of soCs3 
expression. administration of leptin upregulates P-stat3 
only in monocytes from relapsing patients, suggest-
ing that lePr might be involved in clinical relapses in 
patients with ms.20
a recent report has shown that obesity at 18 years of 
age is associated with a greater than twofold increased 
risk of developing ms.21 after adjusting for body size at 
20 years of age, having a large body size at the age of 5 
or 10 years was not associated with an increased risk of 
ms, whereas a large body size at 20 years was associ-
ated with a 96% increased risk, suggesting that the risk 
of developing ms is linked to obesity during adolescence. 
the mechanisms underlying this relationship remain 
unexplained, but we can infer from these data that pre-
vention of obesity in adolescents is likely to reduce the 
probability of developing ms.21 the pathogenesis and 
clinical progression of other autoimmune disorders, 
particularly joint degenerative inflammatory diseases 
such as rheumatoid arthritis and osteoarthritis, have 
been closely linked to obesity,22,23 further reinforcing the 
idea that obesity is one of the factors that underlies 
the high frequency of autoimmune disorders observed 
in developed countries.6
leptin and immune tolerance
a link between leptin and immune tolerance has 
recently been identified. in particular, both in vitro and 
in vivo, leptin can affect the generation, responsiveness 
and pro liferation of treG cells, a key subset of t cells 
that is involved in the control of peripheral tolerance.7,24 
Freshly isolated human treG cells express high amounts 
of lePr and produce substantial amounts of leptin, 
thereby generat ing an autocrine loop that inhibits the 
expansion of the treG cells.7 leptin neutralization blocks 
proliferation of effector CD4+CD25– t cells but promotes 
the expansion of functional treG cells. these opposing 
effects of leptin blockade on the CD4+CD25– t cells and 
treG cells are associated with differential expression of 
intracellular leptin and cell surface lePr in the two 
cell subsets.7
interestingly, in patients with relapsing–remitting ms, 
an inverse correlation between serum leptin levels and 
circulating treG cells is observed. moreover, treatment of 
wild-type mice with the lePr–Fc fusion protein leads to 
increased percentages of treG cells, as well as an ameli-
orated clinical course and delayed progression of eae. 
also, chronic leptin and leptin receptor deficiency in 
mice is characterized by increased percentages, absolute 
numbers and suppressive function of treG cells, which 
return to levels comparable to those in wild-type mice 
after leptin replacement.7,16
the fact that leptin can act as a negative signal for the 
proliferation of treG cells suggests new possibilities for 
leptin-based approaches in the immunotherapy of condi-
tions characterized by low numbers of these cells. leptin 
might act as an endogenous ‘sensing’ factor linking the 
environment (availability of nutrients) to circulating treG 
cell numbers. these effects could be relevant in the wider 
context of nutritional deprivation, which is thought to be 
a factor that increases suscepti bility to infection, and is 
associated with the amelioration of clinic al manifestation s 
of autoimmunity.6
Metabolic status and immune function
molecules that interact functionally with leptin can 
modulate immune function in various ways depend-
ing on the metabolic status. mediators with orexigenic 
( appetite-stimulating) activity, such as ghrelin, neuro-
peptide Y (nPY) and endocannabinoids, have oppo-
site effects from leptin not only on neuro hypothalamic 
control of food intake, but also on the peripheral immune 
response and in autoimmune diseases such as ms (table 1, 
Figure 2).25–28 For example, ghrelin blocks leptin-induced 
secretion of proinflammatory cytokines in human t cells, 
and suppresses eae.25,26 nPY and endocannabinoids 
improve the eae clinical score, ameli orate spasticity, 
and slow the progression of eae.27,28 recent studies have 
shown that the pro inflammatory anorexigenic functions 
of leptin are antagon ized by anti- inflammatory orexi-
genic mediators, and this link might help to explain the 
importance of nutrient availability in relation to immune 
response.25–28 retrospective epidemio logical analyses on 
the clinical history of patients with ms have shown that 
>60% of individuals exhibit reductions in body weight 
before the clinical onset of ms or relapse, suggesting 
that intra thecal secretion of factors with anorexigenic 
effects such as leptin occurs in the early phases of ms 
Table 1 | Opposing effects of anorexigenic and orexigenic mediators
reference Mediator nutritional function immune function effect on eAe
Matarese et al. (2001)13 Leptin Inhibition of food intake (anorexigenic) Proinflammatory Promotion
Theil et al. (2009)26
Bedoui et al. (2003)27
Malfitano et al. (2006)28
Ghrelin
Neuropeptide Y
Cannabinoids
Stimulation of food intake (orexigenic) Anti-inflammatory Inhibition
Abbreviation: EAE, experimental autoimmune encephalomyelitis.
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(G. matarese et al., unpublished work). in support of this 
hypothesis, high levels of leptin are present in the CsF of 
naive-to-treatment ms patients at diagnosis.16
Calorie restriction: a new approach in MS?
a study by Piccio et al. has shown that calorie restriction 
(Cr) can significantly increase survival rates and lifespan 
in experimental animal models of inflammation.29 Cr 
induces multiple metabolic and physiological modifica-
tions, including anti-inflammatory, anti oxidant and 
neuroprotective effects, all of which could be benefici al 
in ms.30
Cr also alters the course of eae. in the Piccio et al. 
study, eae was induced in mice after 5 weeks of Cr or 
ad libitum feeding with a regular diet or a high-fat, high-
 calorie diet.29 the clinical, histological and immuno-
logical outcomes indicated that Cr ameli orates clinical 
eae and reduces inflammation, demyelination and axon 
injury, but does not suppress immune functions. Cr 
was associated with increased plasma levels of cortico-
sterone and adiponectin, and with reduced concentra-
tions of il-6 and leptin. in further studies, calorie intake 
was restricted by 33% or 66% in a monophasic lewis 
rat model, and eae induction was shown to be totally 
inhibited in the latter but not the former group. the rats 
subjected to 66% Cr exhibited depressed immune func-
tion, with fewer t cells in lymphoid organs, and impaired 
t-cell proliferation and cytokine production.31,32
Cr could benefit eae through multiple metabolic 
and cytokine or adipokine changes that ultimately lead 
to a reduced inflammatory response. For example, Cr 
increases plasma levels of corticosterone and adipo-
nectin, both of which are anti-inflammatory, and 
decreases plasma levels of leptin and il-6, which are 
proinflammatory. other possible mechanisms include 
Cr-associated increases in levels of ghrelin, nPY and 
endo cannabinoids, all of which can dampen eae.4,30
environmental factors are believed to have an impor-
tant role in the pathogenesis of ms. this condition is 
particularly prevalent in the western world, where high 
intake of saturated fats of animal origin is common. 
Despite speculation that diet might alter the course of 
ms, only a few randomized controlled studies of dietary 
alterations in ms have been published, none of which 
have involved Cr. studies conducted in the 1980s that 
attempted to use gluten-free or low-fat diets to manage 
ms failed to produce conclusive results and did not raise 
appreciable interest within the scientific community.33,34 
this lack of enthusiasm might be partly ascribed to the 
fact that the molecular mechanisms linking nutrition, 
metabolism and immunity had not been adequately 
explored at this time. in addition, the approaches that 
were employed focused mainly on specific aspects of the 
diet (reduction of gluten or saturated fatty acids), which, 
in contrast to chronic Cr, might not sufficiently influence 
the overall inflammatory immune response.30
Despite the lack of success to date, dietary interven-
tion remains an attractive approach in ms. Cr associated 
with adequate nutrition—which could be safely accom-
plished through proper monitoring—could provide 
additional benefits such as improved insulin sensitivity, 
lower lDl and cholesterol levels and blood pressure and, 
importantly, reduced inflammation.
Drugs that affect metabolism
several pharmacological compounds that affect glucose 
and cholesterol metabolism and adipocyte develop-
ment also have immunomodulatory activities (Box 2). 
such effects are reflected in autoreactive t cells and pro-
inflammatory immune responses in obesity, atheroscleros is 
and ms.35–39
TH
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Stimulate food intake
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Figure 2 | Immune function and metabolic status. a | Leptin from the adipose 
tissue inhibits food intake by activating POMC/CART neurons and inhibiting NPY/
AgRP neurons. By contrast, ghrelin from the stomach stimulates food intake by 
stimulating NPY/AgRP neurons.46 b | Schematic diagram showing that leptin from 
the adipose tissue inhibits food intake and stimulates proinflammatory TH1 
immunity and EAE. Conversely, ghrelin, NPY and endocannabinoids stimulate food 
intake, inhibit the effects of leptin on the hypothalamus, and antagonize the 
proinflammatory effects of leptin on immune cells and EAE. Abbreviations: AgRP, 
agouti-related protein; CART, cocaine- and amphetamine-regulated transcript 
protein; EAE, experimental autoimmune encephalomyelitis; NPY, neuropeptide Y; 
POMC, pro-opiomelanocortin; TH, T helper.
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Current strategies to treat obesity-related metabolic 
disturbances (such as insulin resistance and glucose tol-
erance) involve drugs that not only act on metabolism but 
are now also known to downregulate immune responses. 
examples include metformin, thioazolinediones and 
statins, which are, to varying degrees, capable of reduc-
ing proinflammatory cytokine levels and leptin secretion 
(Box 2).35–37 For example,  metformin—the most widely 
used drug for type 2 diabetes, and the actions of which 
are mediated through the activation of the amP-activated 
protein kinase amPK—has anti-inflammatory proper-
ties and inhibits t-cell-mediated immune responses and 
the production of tH1 or tH17 cytokines, while induc-
ing genera tion of il-10-secreting treG cells.35 in eae, 
metform in reduces the clinical score and inflammation.
thioazolinediones are potent activators of the tran-
scription factor peroxisome-proliferator activated recep-
tor γ (PParγ) and are key players in the development and 
differen tiation of adipose tissue. PParγ agonists down-
regulate the transcription of proinflammatory cytokines 
such as leptin, tnF and il-6. this class of drugs is used in 
the treatment of insulin resistance in obese and type 2 dia-
betic patients for its capacity to exert insulin- sensitizing 
actions.36,38 in eae, these drugs are able to stop disease 
progression and neural inflammation.36 Finally, statins—
inhibitors of 3-hydroxy-3- methylglutaryl coenzyme a 
reductase—inhibit cholesterol synthesis, thereby lowering 
cholesterol levels, and also dampen auto reactive immune 
responses by promoting the release of tH2 cytokines and 
reducing the levels of proinflammatory cytokines such 
as leptin and tnF.37,39 statins are widely used in the treat-
ment of type 2 diabetes and insulin resistance, and have 
been found to be highly effective as therapeutic agents 
in eae.39
in summary, drugs that have long been considered to 
affect metabolism and insulin actions are also immune 
modulators that reduce proinflammatory cytokine levels 
and increase the number and function of treG cells and 
the release of tH2 and regulatory-type cytokines, all of 
which are important in the control of autoimmunity.
Opposing roles of leptin in the CNS
as discussed above, data reported in the literature sug-
gest that leptin is involved in the pathogenesis of both 
experimental autoimmune encephalomyelitis (eae)—
an animal model of ms—and human ms.16 How ever, 
a dichotomous role of leptin on the Cns has emerged, 
with evidence suggesting that this protein can have 
differential effects on myelination, neural cell survival 
and immune-mediated demyelination at various stages 
of the life cycle.40–42
to study the role of leptin in neural development, 
investigators examined the effects of leptin deficiency 
and postnatal treatment with leptin on brain weight, 
neuronal and glial markers, and locomotor activity. 
mice deficient in leptin or its receptors (ob/ob and db/db 
mice, respectively) displayed reduced brain weight and 
an immature pattern of expression of synaptic and glial 
proteins, including elevated levels of growth- associated 
protein in the neocortex and hippocampus, and decrea-
sed levels of syntaxin-1, synaptosomal-associated 
protein-25 (snaP-25) and synaptobrevin throughout 
the brain.40–42 expression of myelin basic protein, PlP 
and glial fibrillary acidic protein was also decreased in 
the neocortex, hippocampus and striatum of ob/ob and 
db/db mice. treatment of ob/ob mice with recombi-
nant leptin increased brain weight and overall protein 
content, improved the locomotor activity of the animals, 
and normalized the levels of growth-associated protein, 
 syntaxin-1 and snaP-25, but had no effect on the expres-
sion of synaptobrevin or glial proteins.40–42 these findings 
suggest that leptin is required for normal neuronal and 
glial maturation in the nervous system of the mouse.
the discovery that leptin has a dichotomous role in 
the Cns is not particularly surprising, as other cytokines 
such as il-6, il-7 and il-15 can exert proinflammatory 
and demyelinating activities (through activation of self-
reactive t cells) as well as promoting neural and myelin 
development.43
Conclusions and future perspectives
leptin is considered to be an attractive immuno -
therapeutic target for reducing inflammation and auto-
immunity. Conditions in which levels of leptin decrease 
dramatically, such as during the stress response of acute 
starvation, have been suggested to be beneficial in auto-
immunity and detrimental during infection.44,45 leptin 
alone is unlikely to be sufficient to determine the outcome 
of autoimmunity or ms, but the observations that leptin 
neutralization can markedly delay the onset and pro-
gression of eae and inhibit myelin- specific autoreactive 
t cells are important. these findings provide proof-
of-principle evidence that leptin modulation in Cns 
autoimmunity—probably in combination with standard 
therapies—could increase treatment efficacy, target multi-
ple proinflammatory pathways, and reduce drug dosages 
to levels that minimize adverse effects.
Box 2 | Drugs that affect metabolism
The following drugs, all of which reduce leptin levels, are 
used to treat metabolic syndrome and insulin resistance, 
and have also been found to inhibit experimental 
autoimmune encephalomyelitis:
Metformin (AMP-activated protein kinase agonist) ■ 35
Thioazolinediones (peroxisome-proliferator activated  ■
receptor γ agonists)36
Statins (3-hydroxy-3-methylglutaryl coenzyme A  ■
reductase inhibitors)37
Review criteria
A comprehensive literature review was performed in 
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“obesity”, “multiple sclerosis”, “EAE”, “metabolism” and 
“nutrition”. Only original articles in the English language 
were included.
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